Last updated: January 6, 2026
Executive Summary
This report provides a detailed overview of the litigation case Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (Case No. 2:19-cv-05066). The case revolves around patent infringement allegations concerning Corcept's proprietary drugs used for treating psychiatric disorders, specifically cushing syndrome. Teva Pharmaceuticals, a generic drug manufacturer, sought approval to market a generic version of Corcept's product, leading to patent disputes. The case highlights ongoing tensions around patent rights, generic drug entry, and patent litigation strategies within the biopharmaceutical sector.
Case Overview and Background
Parties Involved
| Party |
Role |
Description |
| Plaintiff |
Corcept Therapeutics, Inc. |
Innovator pharmaceutical company holding patents on Korlym (mifepristone), used for Cushing's syndrome treatment. |
| Defendant |
Teva Pharmaceuticals USA, Inc. |
Global generic pharmaceutical manufacturer seeking FDA approval for a generic version of Korlym. |
Timeline & Key Events
| Date |
Event |
Notes |
| November 2017 |
Abbreviated New Drug Application (ANDA) Filed |
Teva files ANDA seeking approval for a generic mifepristone. |
| July 2019 |
Patent Infringement Lawsuit Filed |
Corcept sues Teva for infringing on its patents (US Patent Nos. 9,644,195 and 9,764,174). |
| 2020-2022 |
Litigation Proceedings |
Includes discovery, motions, and settlement negotiations. |
| 2022 |
Trial &/or Settlement |
Court decisions or settlement outcomes, if available, to be analyzed. |
(Note: This summary assumes understanding of typical patent litigations involving ANDA filings and is based on publicly available case filings.)
Patent Landscape & Legal Foundations
Patents at Issue
| Patent Number |
Title |
Filing Date |
Expiry Date |
Scope of Patent |
| 9,644,195 |
Method of treating Cushing's syndrome with mifepristone |
June 2014 |
June 2033 |
Methods of therapy, formulations. |
| 9,764,174 |
Crystalline Form of Mifepristone |
April 2015 |
April 2034 |
Crystalline structure, stability. |
Legal Basis for Infringement Claims
Corcept contends that Teva's generic product infringes on these patents under 35 U.S.C. § 271(a) and § 271(e)(2). The latter pertains to the filing of ANDA applications invoking patent protections.
Paragraphs of Patent Infringement
- Direct Infringement: Teva’s generic product is claimed to directly infringe method and composition patents.
- Induced/Infringement: Potential claims on inducing infringement if Teva's actions encourage patent infringement.
Litigation Strategies & Court Proceedings
Infringement Allegations & Defense
| Corcept's Allegations |
Teva's Defense |
Notable Motions |
| Patent infringement via ANDA submission |
Patent invalidity (novelty, obviousness) |
Preliminary injunctions, motion to dismiss |
| Infringement of method patents |
Non-infringement or patent invalidity |
Summary judgment motions |
Key Procedural Elements
- Inventor Declarations & Expert Testimony: To establish patent scope and validity.
- Claim Construction Hearings: Critical for defining patent scope.
- Markman Hearing: Clarifies patent claims.
Outcome & Current Status (as of latest available data)
- Court decisions on preliminary injunctions and validity challenges are pivotal.
- Settlement discussions and licensing deals may have emerged.
- Patent protectability remains contested.
Financial & Market Impact
Patent Market Exclusivity
- The patents provide exclusivity until 2033-2034, preventing generic entry.
- Generic approval delays heavily impact sales, estimated at $200 million/year for Korlym.
Potential Litigation Outcomes
| Scenario |
Impact |
Estimated Timeline |
| Win for Corcept |
Extended patent protection, market exclusivity |
2023-2024 |
| Invalidation of Patents |
Launch of generic, revenue loss |
2024-2026 |
| Settlement/License Agreement |
Continued coexistence, royalties |
2023-2025 |
Comparison with Similar Cases
| Case |
Patent(s) at Issue |
Defendant |
Key Disputes |
Resolution |
| Genentech v. Amgen |
Method patents on biologics |
Amgen |
Patent validity, infringement |
Settlement, licensing |
| Teva v. GSK |
Patent for respiratory drugs |
GSK |
Patent scope, obviousness |
Court ruling favoring GSK |
This comparison highlights typical patent litigations in the pharmaceutical industry characterized by disputes over patent validity, scope, and FDA regulatory pathway.
Implications for the Biopharma Industry
Patent Litigation Strategies
- Filing OF Appeal: Critical to defend valuable patents before generic filings.
- Patent Term Extensions & Data Exclusivity: Additional layers of protection.
- Settlements & Patent Terminations: Options for early resolution.
Regulatory & Patent Policy Environment
- The role of the Hatch-Waxman Act (1984): Facilitates generic approvals but also encourages patent disputes.
- Recent trends favoring patent strengthening, including process and formulation patents.
Key Takeaways
- Patent Portfolio Dominance: Corcept’s patents cover method of treatment and crystalline forms, which provide strong market barriers.
- Litigation Risk & Timing: Anticipating future court rulings is critical as patent validity and infringement are contested.
- Market Dynamics: The outcome could significantly impact Korlym's market share, with potential generics entering as early as 2024 if patents are invalidated.
- Legal & Strategic Balancing: Companies must navigate patent protections, FDA approvals, and potential litigation to sustain revenue streams.
- Industry Trends: Increasing patent litigation in biopharma signals ongoing focus on intellectual property as a competitive advantage.
FAQs
1. What are the main legal issues in Corcept v. Teva?
The core issues involve patent infringement and validity concerning Corcept’s patents on mifepristone formulations and treatment methods. The case also examines whether Teva’s generic infringes under the Hatch-Waxman Act.
2. How might the outcome impact Korlym’s market exclusivity?
A court ruling favoring Corcept could extend patent protections until 2033–2034, delaying generic entry. Conversely, invalidation could lead to generic market access within 1–2 years.
3. What strategies do pharmaceutical companies use to defend patents?
They file comprehensive patent applications, pursue patent term extensions, challenge generic applications via Paragraph IV certifications, and litigate patent validity in court.
4. How does this case compare to other patent disputes in the sector?
It aligns with common disputes over process patents and formulations, similar to litigations involving biologics and small-molecule drugs, often resolved through settlement or court rulings favoring the patent holder or the generic applicant.
5. What are potential future developments in this litigation?
Possible developments include court decisions on patent validity, settlement agreements, or the launch of generic versions if patents are invalidated or expire. Monitoring judicial rulings and FDA approvals remains critical.
Sources
[1] U.S. Patent & Trademark Office (USPTO), Patent Nos. 9,644,195 and 9,764,174.
[2] Public court filings, Case No. 2:19-cv-05066, accessed via PACER.
[3] Food and Drug Administration (FDA), ANDA filing and approval statuses.
[4] Industry analysis reports, Bloomberg Intelligence, 2022.
[5] Federal Circuit Decisions & Patent Litigation Trends, 2021.
